Search Prime Grants

W81XWH2220028

Cooperative Agreement

Overview

Grant Description
Immune therapeutics that combine fast-acting monoclonal antibody and a vaccine for long-lasting protection against Plasmodium falciparum malaria.
Awardee
The Geneva Foundation
Grant Program (CFDA)
12.420 - Military Medical Research and Development
Awarding Agency
U.S. Army Medical Research Acquisition Activity (USAMRAA) [DoD - USA - MEDCOM - MRDC]
Funding Agency
Medical Command (MEDCOM) [DoD - USA]
Place of Performance
Tacoma, Washington 984024437 United States
Geographic Scope
Single Zip Code
Related Opportunity
None
The Geneva Foundation was awarded Cooperative Agreement W81XWH2220028 worth $1,672,094 from Medical Command in September 2022 with work to be completed primarily in Tacoma Washington United States. The grant has a duration of 3 years and was awarded through assistance program 12.420 Military Medical Research and Development.

Status
(Ongoing)

Last Modified 5/24/22

Period of Performance
9/30/22
Start Date
9/29/25
End Date
86.0% Complete

Funding Split
$1.7M
Federal Obligation
$0.0
Non-Federal Obligation
$1.7M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to W81XWH2220028

Additional Detail

Award ID FAIN
W81XWH2220028
SAI Number
None
Award ID URI
None
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Other
Awarding Office
W81XWH W4PZ USA MED RSCH ACQUIS ACT
Funding Office
W91ZSQ W03J HQ CO USA MED DEV MAT CM
Awardee UEI
TR9RX33188T4
Awardee CAGE
1D2D1
Performance District
06
Senators
Maria Cantwell
Patty Murray
Representative
Derek Kilmer
Modified: 5/24/22